Bio-Rad Laboratories, Inc. (BIO)
Upgrades & Downgrades
Latest BIO news
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
17 June 2022
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
6 June 2022
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.
Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade
25 May 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positiv...
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
29 April 2022
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q1 2022 Results - Earnings Call Transcript
28 April 2022
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2022 Earnings Conference Call April 28, 2022 6:00 PM ET Company Participants Ed Chung - Head of Investor Relations Ilan Daskal - Executive Vice President & Ch...
Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates
28 April 2022
Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
27 April 2022
Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
19 April 2022
Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
Bio-Rad to Report First-Quarter Financial Results, Thursday, April 28, 2022
18 April 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fir...